Congress strips immunity shield from pandemic drug makers, restores right to sue
H.R. 4388 — PREP Repeal Act · Filed by Thomas Massie (R-KY) · 3 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill repeals two sections of federal law (319F-3 and 319F-4 of the Public Health Service Act) that currently shield pharmaceutical manufacturers and other entities from liability when they develop, distribute, or administer emergency medical countermeasures (drugs, vaccines, devices) during declared public health emergencies under the PREP Act. The repeal restores the right of citizens to sue for injuries caused by these products in federal or state court, effective immediately for pending and future claims.
Why we flagged it
The bill's core function is to eliminate federal immunity for pharmaceutical manufacturers and other entities under the PREP Act, restoring private rights of action for injury claims. This is fundamentally a deregulatory reversal—removing a shield rather than imposing new restrictions.
What the text implies
- Retroactive application to pending claims means manufacturers face immediate exposure to lawsuits filed before enactment, potentially creating a sudden litigation surge and settlement pressure.
- The bill does not establish a statute of limitations or claims procedure, leaving the scope and timeline of potential litigation undefined and potentially unlimited.
The full analysis lists 5 implications of this text.
Who stands to gain
personal injury law firms; class action attorneys; litigation finance companies